Get the Stockscreener App
7.12
3.39%
-0.25
After Hours:
7.12
Kyntra Bio Inc stock is traded at $7.12, with a volume of 8,914.
It is down -3.39% in the last 24 hours and up +2.15% over the past month.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
See More
Previous Close:
$7.37
Open:
$7.35
24h Volume:
8,914
Relative Volume:
0.29
Market Cap:
$28.81M
Revenue:
$6.44M
Net Income/Loss:
$-58.21M
P/E Ratio:
0.2277
EPS:
31.2684
Net Cash Flow:
$-4.86M
1W Performance:
-2.47%
1M Performance:
+2.15%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.09
$7.36
1-Week Range:
$7.02
$7.455
52-Week Range:
$6.32
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Name
Kyntra Bio Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO
Compare KYNB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
7.12 | 29.83M | 6.44M | -58.21M | -4.86M | 31.27 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
View All
Kyntra Bio Inc Stock (KYNB) Latest News
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
What date does Kyntra Bio Inc's (KYNB) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Kyntra Bio, Inc. Files 8-K Current Report with SEC – Company Information, Address, and NASDAQ Listing Details - Minichart
Kyntra Bio Faces Nasdaq Compliance Challenge After Revenue Shift - TipRanks
Kyntra Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Nasdaq warns Kyntra Bio (NASDAQ: FGEN) over Global Select listing test - Stock Titan
KYNB Stock Price, Quote & Chart | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference - Bitget
KYNB PE Ratio & Valuation, Is KYNB Overvalued - Intellectia AI
FGEN SEC FilingsFibrogen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Kyntra Bio (MEX:KYNB) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
Kyntra Bio, Inc.Common Stock (NQ: KYNB - FinancialContent
KYNB Technical Analysis | Trend, Signals & Chart Patterns | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
If You Invested $1,000 in Fibrogen Inc (FGEN) - Stock Titan
Advancing Pipeline and 2026 Clinical Catalysts Underpin Buy Rating on Kyntra Bio - tipranks.com
Kyntra Bio, Inc. 2023 Annual Report: Business Overview, Risk Factors, and Financial Highlights - Minichart
Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline with ... By GuruFocus - Investing.com Canada
Kyntra Bio Inc (KYNB) Q4 2025 Earnings Call Highlights: Navigati - GuruFocus
Maintaining a Hold on Kyntra Bio Amid Pipeline Refocus and Pending Clinical Inflection Points - TipRanks
Kyntra Bio 2025 Review: Clinical Progress on Cancer Drugs and Future OutlookNews and Statistics - IndexBox
KYNB: Cash runway extended to 2028 as FG-3246 and roxadustat advance in key late-stage trials - TradingView
Kyntra Bio (KYNB) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript - The Globe and Mail
Kyntra Bio, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KYNB) 2026-03-16 - Seeking Alpha
Kyntra Bio: Fourth Quarter Financial Overview - Bitget
Kyntra Bio: Q4 Earnings Snapshot - marketscreener.com
Kyntra Bio reports $6.44M revenue, $45.37 EPS on divestiture gain - TradingView
Kyntra Bio (NASDAQ: KYNB) pivots to oncology and advances FG-3246, roxadustat - Stock Titan
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
KYNB: Revenue fell but net loss improved; clinical and regulatory milestones achieved - TradingView
Kyntra Bio (Nasdaq: KYNB) unveils 2025 results, FG-3246 and roxadustat plans - Stock Titan
New prostate cancer drug trial advances as Kyntra Bio cuts 2025 loss - Stock Titan
KYNB: Operating losses narrowed sharply in 2025 after China divestiture and cost cuts; pipeline focus continues - TradingView — Track All Markets
FibroGen (KYNB) Set to Announce Q4 Earnings with Significant Dec - gurufocus.com
KYNB: Lead oncology and anemia programs advance with strong data, regulatory clarity, and commercial promise - TradingView
Kyntra Bio : Corporate Presentation – March 2026 - marketscreener.com
Kyntra Bio (KYNB) CEO reports 277-share tax withholding event - Stock Titan
Tax withholding slightly trims Kyntra Bio (KYNB) CFO share holdings - Stock Titan
Kyntra Bio (KYNB) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results - Bitget
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kyntra Bio (KYNB), Crispr Therapeutics AG (CRSP) and GoodRx Holdings (GDRX) - The Globe and Mail
KYNB Price History for Kyntra Bio Stock - Barchart.com
KYNB | Kyntra Bio, Inc. Common Institutional Ownership - Quiver Quantitative
Kyntra Bio reports prostate cancer trial results at ASCO GU - Investing.com South Africa
What's Going On With Kyntra Bio Stock Tuesday? - Bitget
Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246 - TipRanks
Kyntra Bio reports prostate cancer trial results at ASCO GU By Investing.com - Investing.com Australia
KYNB to Present FG-3246 Trial Data at ASCO GU 2026 - GuruFocus
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - marketscreener.com
KYNB Stock Price, News & Analysis - Stock Titan
Kyntra Bio Inc Stock (KYNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):